Policy & Regulation
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic Liver Failure
13 November 2019 - - Belgium-based cell-based medicines and liver disease specialist Promethera Biosciences SA has published updated clinical data from the ongoing phase 2a study (HEP101) of its lead product candidate HepaStem in patients with Acute-on-Chronic Liver Failure or acute decompensation at high risk of developing ACLF, the company said.
The data were presented in an oral presentation at the annual meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Promethera's principal investigator Prof. F. Nevens, KULeuven, Belgium.
The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.
Currently, liver transplant is the only rescue treatment for patients suffering from ACLF and to a lesser degree for patients with acute decompensation of the liver.
There are no other existing therapies that can rescue the end-stage-liver failure. Promethera is developing HepaStem as an alternative to transplant; it consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions.
These liver derived signaling stem cells migrate through the blood stream to reach the liver, where they support the tissue regeneration via their potent secretome.
In the trial HEP101, HepaStem has been intravenously infused in single or repeated injections in multiple ascending doses in patients to assess the tolerability and the safety profile of the treatment.
The trial which recruited a total of 24 patients, including 16 patients with ACLF and 8 patients with AD has met its primary endpoint.
With one or two repeated doses up to 1.2 m cells per kilogram of body weight, no adverse events related to HepaStem occurred and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion.
The demonstrated safety of two infusions of 1.2 m cells per kilogram of body weight provide solid guidance for conducting the subsequent trials.
In addition to the positive safety profile, the study has shown trends in efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score, Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation.
Promethera plans to demonstrate the efficacy of HepaStem at 1m cells per kilogram of body weight in ACLF with a large multicentric double blind placebo-controlled trial (HEP102). The study HEP102 is expected to start end 2019.
Promethera Biosciences is in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation.
Its lead clinical programme, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties.
In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options.


Related Headlines